by Raynovich Rod | Feb 2, 2012 | BIOgraph, Clinical Diagnostics and Tools
Early Player in Genetic Testing and Personalized Medicine Reloads RGDX Stock Trades Up 36% on Volume of 105k Shares at $1.60 Response Genetics (RGDX) announced today that it has entered purchase agreements with private investors including current holders to raise...
by Rod Raynovich | Apr 4, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Platform Technologies Are In Demand: M&A Driver Intact Exact Sciences (EXAS $7.50) continued to run today up 3% and 1.3 pts in five days on no apparent news except presentations at recent investment conferences. The Company is developing a molecular diagnostic...
by Rod Raynovich | Nov 30, 2010 | 2023-24 Life Science Portfolios, BIOgraph
Gen-Probe (GPRO,$51.60) announced yesterday that it submitted a Premarket Approval Application(PMA) the the FDA for its APTIMA HPV (human papillomavirus ) assay , a molecular diagnostic test that detects high-risk HPV infections that are associated with cervical...
by Rod Raynovich | Nov 8, 2010 | 2023-24 Life Science Portfolios, BIOgraph
Immucor (BLUD) stock was up 5.7% to $18.91 on news that the DOJ closed its anti-trust investigation. The stock hit a low in early October when it slashed guidance due to lower utility of blood transfusion services.The Company is a leader in automated blood...
by Rod Raynovich | Oct 28, 2010 | BIOgraph
EXAS -Big Sell-Off on the News Exact Sciences (EXAS) was down 20% today after presenting its first validation data on the performance of its experimental, non-invasive colorectal cancer test. As of midday trading the stock was around $6.90 on huge volume over 5.5 M...
by Rod Raynovich | Oct 22, 2010 | BIOgraph
GE announced the purchase of Clarient (CLRT) for $5/share or $580M, a 34% premium over Clarient’s previous closing price. Revenues forecasted for 2011 and 2012 are at $114M and $136M respectively, pricing the deal at a Price to Sales of 4.25 to 5X. Revenues for...
by Rod Raynovich | Sep 20, 2010 | 2023-24 Life Science Portfolios, BIOgraph
Continuing from Part 1 here are some specific comments on interesting companies. Adeona Pharmaceuticals (AEN) Amex ($0.83) Market Cap $19M, $25M Sh. Outstanding Adeona is a development stage drug Company focused in CNS that in -licenses clinical stage product...
by Rod Raynovich | Apr 20, 2010 | RAG
Yesterday we presented an overview of the use of Biomarkers(BM’s) for predictive use in the treatment of Lung Cancer. Here are some additional summaries from the American Association for Cancer Research(AACR) meeting on Monday.Researchers from Fox Chase Cancer...
by Rod Raynovich | Feb 16, 2010 | RAG
Many of the issues coming out of the healthcare reform discussion: rising medical costs, Medicare budget, need for better clinical outcomes, push for biogenerics have caused concern among investors and limited returns in the healthcare sector. Although M&A...
